EP-1347 "Risk adapative" dose prescription in central NSCLC lesions in early stage NSCLC and lung metastases. (April 2019) - Rigo, M.; Giaj-Levra, N.; Figlia, V.; Mazzola, R.; Nicosia, L.; Ricchetti, F.; Ruggieri, R.; Alongi, F.